Do Not Start Jardiance During Active AKI
You should NOT initiate empagliflozin (Jardiance) in a patient who currently has acute kidney injury (AKI). Wait until the AKI has resolved and the patient's volume status is stable before starting this medication.
Key Reasoning
FDA Label Guidance Takes Priority
The FDA label for Jardiance explicitly warns about volume depletion as a critical concern, stating that SGLT2 inhibitors can cause intravascular volume depletion which may manifest as symptomatic hypotension or acute transient changes in creatinine 1. The label specifically instructs: "In patients with volume depletion, correct this condition before initiating JARDIANCE" 1. Active AKI often involves or is complicated by volume depletion, hemodynamic instability, or evolving kidney injury—all contraindications to starting this medication.
Guideline Recommendations Support Sick Day Management
The 2022 Canadian Cardiovascular Society guidelines explicitly state that "SGLT2i should be stopped temporarily in the setting of concomitant dehydrating illness as part of 'sick day' management" 2. While this refers to stopping existing therapy, the principle applies even more strongly to initiation—you wouldn't start a medication during the exact clinical scenario where you'd otherwise hold it.
The 2022 ADA/KDIGO consensus report reinforces this, recommending to "Hold SGLT2i during illness" and emphasizing monitoring for hypovolemia 3. The guidelines note that while SGLT2i use "appears to protect patients from AKI" in the long term, this refers to prevention in stable patients, not initiation during active injury 3.
Clinical Algorithm for Jardiance Initiation Post-AKI
Step 1: Ensure AKI Resolution
- Wait until serum creatinine is stable or returning toward baseline
- Confirm the patient is no longer in the acute injury phase
- Document that eGFR is ≥20 mL/min/1.73 m² (the minimum threshold for empagliflozin) 3
Step 2: Assess Volume Status
- Ensure euvolemia before initiation
- Patient should not be on aggressive diuresis
- No signs of dehydration or hypotension
- Stable blood pressure without orthostatic changes
Step 3: Evaluate Precipitating Factors
- Ensure the cause of AKI has been addressed
- No ongoing acute illness, sepsis, or dehydrating conditions
- Patient is eating and drinking normally
- No planned surgeries (hold at least 3 days before surgery) 1
Step 4: Safe Initiation
Once stable, empagliflozin can be started and may actually provide renoprotective benefits going forward—trial evidence shows SGLT2i reduce recurrent AKI risk 4 and protect against future kidney injury 5, 6.
Important Caveats
The Expected eGFR Dip Is Not AKI
Once you do start Jardiance (after AKI resolution), expect a temporary 15-25% decrease in eGFR within 1-3 months 2. This is a hemodynamic effect from reduced intraglomerular pressure—similar to ACE inhibitors—and is not a sign of new AKI. This should not prompt discontinuation 3.
Long-Term Benefits Are Real
Research shows empagliflozin reduces recurrent AKI by approximately 50% (incident rate ratio 0.51) 4, decreases risk of AKI hospitalization by 34% 6, and provides renoprotection 5, 7. But these benefits apply to stable patients, not those in active kidney injury.
Monitor Closely After Starting
- Reassess volume status and kidney function within 1-2 weeks
- Reduce diuretic doses if needed to prevent excessive volume depletion
- Educate patients on sick day rules: stop Jardiance during acute illness, vomiting, diarrhea, or reduced oral intake 3
Bottom line: Active AKI is a temporary contraindication. Stabilize the patient first, then initiate Jardiance for its proven long-term cardiorenal benefits.